Ecog-acrin Cancer Research Group
Clinical trials sponsored by Ecog-acrin Cancer Research Group, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New MRI technique could sharpen prostate cancer staging Results expected Dec 2026 (estimated)
- New drug combos tested to improve lymphoma control in younger patients Results expected Dec 2026 (estimated)
- Massive myeloma trial tests which combo works best Results expected Dec 2026 (estimated)
- Green tea extract tested to keep prostate cancer in check Results expected Dec 2026 (estimated)
- PET scans may let melanoma patients stop treatment sooner Results expected Jan 2027 (estimated)
-
Experimental lung inflammation treatment trial shuts down after just one patient
Disease control Stopped earlyThis phase 2 trial aimed to see if infliximab and intravenous immunoglobulin (IVIG) could help cancer patients with severe lung inflammation that didn't respond to steroids. Only one patient was enrolled before the study was terminated, so no meaningful results were obtained. The…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Melanoma drug combo trial halted after just 3 patients
Disease control Stopped earlyThis study tested two drugs, encorafenib and binimetinib, given before surgery to people with stage IIIB-D melanoma that had spread to lymph nodes. The goal was to see if the drugs could shrink or eliminate the cancer before removal. The trial was stopped early after enrolling on…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Melanoma drug combo trial halted early – only 5 patients enrolled
Disease control Stopped earlyThis study tested whether adding hydroxychloroquine (a malaria drug) to standard targeted therapy (dabrafenib and trametinib) could help control advanced melanoma that had spread or could not be removed by surgery. It was designed for people with a specific gene mutation (BRAF V6…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC